Literature DB >> 810280

The immune response to phichi174 in man. IV. Primary and secondary antibody production in patients with chronic lymphatic leukaemia.

T J Hamblin, J V Jones, D B Peacock.   

Abstract

Ten patients with chronic lymphatic leukaemia (CLL) were injected with the antigen phichi174 intravenously on two occasions to test their capacity for antibody production. Nine out of ten patients failed to develop a primary response, and five out of ten failed to develop a secondary response. Only one out of the ten of the secondary responses fell within the normal range. There was evidence of defective switching from IgM to IgG antibody in two out of three cases in which the immunoglobulin class of antibody in the secondary response was determined. The severity of the immunoparesis in CLL is related to the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810280      PMCID: PMC1538244     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  6 in total

1.  IMMUNOLOGICAL DEFICIENCY DISORDERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA.

Authors:  L CONE; J W UHR
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

2.  Quantitative antibody studies in man. III. Antibody response in leukemia and other malignant lymphomata.

Authors:  D L LARSON; L J TOMLINSON
Journal:  J Clin Invest       Date:  1953-04       Impact factor: 14.808

3.  Quantitative antibody studies in man. II. The relation of the level of serum proteins to antibody production.

Authors:  D L LARSON; L J TOMLINSON
Journal:  J Lab Clin Med       Date:  1952-01

4.  The immune response to thetaX 174 in man. I. Primary and secondary antibody production in normal adults.

Authors:  D B Peacock; J V Jones; M Gough
Journal:  Clin Exp Immunol       Date:  1973-04       Impact factor: 4.330

5.  Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.

Authors:  H D Ochs; S D Davis; R J Wedgwood
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

6.  Circulating antibodies in reticuloses.

Authors:  M BARR; G H FAIRLEY
Journal:  Lancet       Date:  1961-06-17       Impact factor: 79.321

  6 in total
  7 in total

1.  Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.

Authors:  J A Tooze; D H Bevan
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  A Morgan; J Eaves; J W Mockford; V Malkovska
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Restoration of "normal" membrane function in CLL cells by patients' serum.

Authors:  C M Lewis; G D Pegrum
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

4.  Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

Authors:  H V Marquart; K Grønbaek; B E Christensen; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

5.  Studies on the immune status of children with acute lymphocytic leukaemia. II. In remission with and without cytostatic treatment.

Authors:  W H Hitzig; H J Plüss; P Joller; U Pilgrim; H Tacier-Eugster; M Jakob
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

6.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

7.  Detection and characterization of a novel bisegmented double-stranded RNA virus (picobirnavirus) from rabbit faeces.

Authors:  C Gallimore; D Lewis; D Brown
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.